Latest news with #visionimpairment
Phone Arena
2 days ago
- Business
- Phone Arena
Solos' new partnership brings real-world use cases that you need to already excellent smart glasses starting today
Solos — which makes some pretty neat smart glasses to challenge the Meta Ray-Ban — has just partnered with Envision. Through this collaboration, the app 'Ally' is now supported on the Solos AirGo, bringing practical use to the glasses for people whose vision is on the Solos AirGo will enable its users to be able to carry out a lot of tasks with AI-powered assistance backing them up. For example, the glasses can read text from books, mail, menus, and signs for the user. The AirGo will also be able to recognize people and places, so users can simply ask their glasses where they currently are, or who might be approaching them. Furthermore, the Solos AirGo — powered by Ally — can remember context for future conversations, or read you a document. And, of course, the glasses can also answer questions, provide reminders, or carry out other tasks that current AI models are quite good Meta, Google, Samsung, and Apple vie for an emerging industry, it's nice to see a company also keeping other helpful applications of the technology in mind. The Meta Ray-Ban smart glasses were an unprecedented success, and glasses like the Solos AirGo are a bridge between the smartphone of today and the true AR smart glasses of tomorrow. Using Ally on the Solos AirGo smart glasses. | Image credit — Solos Envision's Ally app's compatibility with the Solos AirGo smart glasses begins today, and all tiers of the glasses will get a month-long free trial of Ally Pro. If you find the app helpful with your glasses, then you know that you've just found what will possibly be your best purchase in years. You can order a pair of the Solos AirGo smart glasses here. Solos' smart glasses offer plenty of reasons for consumers to choose them over competitors. For example, shortly after bringing AI-powered features to the glasses, Solos introduced an extra mode of privacy. The Solos AirGo Vision, launched last year, allowed users to swap frames for whenever they didn't want the camera to be able to see their surroundings. Whenever the industry finally moves on to smart glasses with displays, I suspect Solos will follow with some pretty nifty offerings of its own.
The Sun
08-07-2025
- Entertainment
- The Sun
Darts star opens up on debilitating health condition that also affects his daughter as he tries to help find a cure
DARTS star Ryan Searle has opened up on his struggles in finding a cure to his and his daughter's debilitating eye disease. Searle, known as Heavy Metal for his love of rock music, chunky 34g arrows and rockstar hair, suffers from Dominant Optic Atrophy. 3 3 The PDC darts star, 37, is currently the world No19 and has reached the last-16 at the World Championship three times. The genetic condition causes him blurred vision, with Searle admitting he has "learned to live" with its effects. Searle explained to Darts News: 'DOA basically means there's reduced blood flow to my damaged optic nerve. 'I wear contact lenses now, so it's not as bad. My vision's not as blurry anymore. 'I don't have to keep stopping to ask what I've scored or what's left, and that's helped my game a lot.' When asked if was legally blind, Searle joked: 'It's getting there — pretty close. 'But no, not quite. I can still legally drive, just about.' Searle only discovered he had the condition in the past couple of years — after his daughter Amelia was diagnosed. 3 He said: 'It comes in different severities — mine's fairly bad, but hers is really bad. 'She's registered as visually impaired and she'll probably never be able to drive. Darts star Ryan Searle says he is not one for the limelight 'I've been speaking with a charity who are trying to raise money to find a cure because there isn't one. 'Whatever vision you're born with, that's what you're stuck with. 'I'm going to have a patch on my shirt soon for the charity, to try and raise awareness and hopefully help get closer to a cure.' Despite his rise up the rankings, Heavy Metal is yet to win a major TV tournament. Searle came closest in 2021, losing in the Players Championship Finals to Peter Wright. He previously said: 'I've learned to live with it, but it does affect me - I can't always see where my dart lands. 'That's why you'll often see me asking the referee what I've thrown.' Searle also shares a son with wife Sophie Cosh.
Medscape
29-05-2025
- General
- Medscape
Study Underscores Need for Eye Exam in Psych Disorders
Individuals older than 50 years with bipolar or major depressive disorder were more likely to have retinal disease, and those with a diagnosis of retinal disease and a psychiatric illness were at sharply higher risk for impaired vision than those with retinal disease alone. METHODOLOGY: Researchers conducted a retrospective cohort analysis of adults aged 50-89 years with a diagnosis of schizophrenia (n = 160,414; mean age, 65 years), bipolar disorder (n = 391,440; mean age, 63 years), or major depressive disorder (n = 1,962,380; mean age, 67 years), matched with people without psychiatric conditions. They also examined how comorbid psychiatric disorders affected vision impairment in patients with retinal disease, focusing on those with schizophrenia (n = 8880), bipolar disorder (n = 22,678), or major depressive disorder (n = 265,544); these patients were matched to individuals with retinal disease but no history of psychiatric disorders. The primary outcome was a diagnosis of retinal disease, including chronic or age-related conditions, and the secondary outcome was having impaired vision. TAKEAWAY: Individuals with bipolar disorder showed a 4%-15% higher risk for retinal disease across all age groups older than 60 years (relative risk [RR], 1.04; 95% CI, 1.01-1.08 for ages 60-69 years; RR, 1.15; 95% CI, 1.10-1.20 for ages 70-79 years; and RR, 1.15; 95% CI, 1.07-1.23 for ages 80-89 years). Major depressive disorder also was associated with an increased likelihood of retinal disease in people aged 50-59 years (RR, 1.84; 95% CI, 1.79-1.89), with sustained increase in risk among those aged 60-69 years, 70-79 years, and 80-89 years. Among individuals with retinal disease, those with a diagnosis of major depressive disorder were about 50% more likely to have impaired vision (RR, 1.51; 95% CI, 1.48-1.54) as were those with a diagnosis of bipolar disorder (RR, 1.33; 95% CI, 1.25-1.42). While individuals with schizophrenia were less likely to be diagnosed with retinal disease (RR < 1 across all age groups), those who had both schizophrenia and retinal disease were 35% more likely to experience impaired vision as were those with retinal disease alone (RR, 1.35; 95% CI, 1.23-1.48). IN PRACTICE: 'Individuals with psychiatric disorders are often considered a vulnerable population due to systemic, social, and biologic factors that contribute to worse health outcomes compared to the general population,' the authors of the study wrote. 'Psychiatric disorders are also associated with comorbidities such as obesity, diabetes, and metabolic syndrome that are known to increase risk of retinal disease such as diabetic retinopathy. Our findings suggest the need for closer monitoring of retinal disease and visual impairment in individuals with psychiatric disorders.' SOURCE: This study was led by Jeffrey Chu of the Case Western Reserve University School of Medicine in Cleveland. It was published online on May 20, 2025, in Eye . LIMITATIONS: The retrospective nature of this study and potential variations in coding practices among clinicians and institutions limited the findings. Data for optical coherence tomography and visual acuity were unavailable in the network database. Additionally, unaccounted variables such as use of medication, duration of psychiatric disorders, lifestyle factors like smoking, socioeconomic status, and healthcare access may have introduced confounding effects that could not be controlled for. DISCLOSURES: This study received support from the Clinical and Translational Science Collaborative through a National Institutes of Health grant, along with partial support from some other sources. Some authors disclosed receiving personal fees, research fees, consulting fees, and speaking fees from several pharmaceutical companies.
